Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

Max H Schubert¹, Keith A Young, Paul B Hicks

¹Department of Psychiatry and Behavioral Science, Neuropsychiatry Research Program, Texas A&M University System Health Science Center College of Medicine, Central Texas Veterans Health Care System, Temple, Texas, USA.

|June 30, 2006

Summary

Galantamine, a cholinesterase inhibitor, improved cognitive function, specifically attention and memory, in schizophrenia patients stabilized on risperidone. This adjunctive treatment offers potential for better functional outcomes.

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Schizophrenia is characterized by significant cognitive impairments across multiple domains.
Galantamine, a cholinesterase inhibitor, has demonstrated cognitive benefits in Alzheimer's disease patients.

Purpose of the Study:

To investigate the efficacy of galantamine as an adjunctive treatment for cognitive deficits in schizophrenia.
To assess the impact of galantamine on cognitive performance in patients stabilized on risperidone.

Main Methods:

A randomized, double-blind, placebo-controlled trial involving 16 schizophrenia or schizoaffective patients on risperidone.
Patients received either galantamine (n=8) or placebo (n=8) for eight weeks.
Cognitive performance was evaluated using the Repeatable Battery for Assessment of Neuropsychological Status (RBANS).

Main Results:

Galantamine treatment led to a significant overall improvement in cognitive performance (RBANS Total scale score).
Specific improvements were noted in Attention and Delayed Memory subscales, approaching normalized cognitive function.
No exacerbation of extrapyramidal symptoms was observed; clinical symptoms improved in both groups.

Conclusions:

Adjunctive galantamine therapy enhances memory and attention in schizophrenia patients on risperidone.
This improvement in cognitive domains presents an opportunity to improve overall functional outcomes.
Galantamine shows promise as a therapeutic option for cognitive dysfunction in schizophrenia.

Related Experiment Videos

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

Related Concept Videos

Single-cell transcriptomic and chromatin dynamics of the human brain in PTSD.

A multi-omic approach implicates novel protein dysregulation in post-traumatic stress disorder.

Decoding the transcriptomic signatures of psychological trauma in human cortex and amygdala.

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder.

Common genetic variation impacts stress response in the brain.

Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report.

Topological data analysis communities reveal gene-environment-brain subtypes of major depression in UK Biobank and multi-site cohorts.

Mega-analysis of Structural Brain Imaging in Functional Neurological Disorder.

Human Cellular Models of Autism and Related Conditions.

Translational Relevance of the MAM Model in Schizophrenia : A Systematic Review of Behavioral and Neurobiological Findings.

Domain-Derived Biomarkers of Treatment Response in Major Depressive Disorder: An Activation Likelihood Estimation Neuroimaging Meta-Analysis.

Functional connectivity of orbitofrontal cortex predicts cocaine relapse: Protective and risk circuits, individual differences, and neuromodulation implications.

Validation and Comparison of Non-stationary Cognitive Models: A Diffusion Model Application.

Leveraging Psychophysics to Infer the Mechanisms of Encoding Change in Vision.

Computational Modeling Reveals Minimal Vigilance Changes in a Cognitive Monitoring Task.

Rapid tobacco surveillance among young people in six states: Methods and findings from the Center for Rapid Surveillance of Tobacco Youth and Young Adult Cohort.

Dual-task gait assessment using n-back testing during self-paced treadmill walking in virtual reality: reliability and baseline characterisation for future clinical application.

Autonomic-salience stability as a candidate Gate for awake low-dose ketamine: a systems neuroscience framework with a clinical anchor.

Related Experiment Videos

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

Area of Science:

Background:

Purpose of the Study:

Main Methods:

Main Results:

Conclusions:

Related Concept Videos

Related Articles